Last Updated: November 16, 2026

Investigational Drug Information for TVB-2640

« Back to Dashboard


What is the drug development status for TVB-2640?

TVB-2640 is an investigational drug.

There have been 12 clinical trials for TVB-2640. The most recent clinical trial was a Phase 2 trial, which was initiated on November 18th 2021.

The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Sagimet Biosciences Inc., Ascletis Pharmaceuticals Co., Ltd., and 3V Biosciences, Inc.

There are one hundred and sixteen US patents protecting this investigational drug and one hundred and eight international patents.

Recent Clinical Trials for TVB-2640
TitleSponsorPhase
A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionSagimet Biosciences Inc.Phase 1
Phase I Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerSagimet Biosciences Inc.Phase 1
Phase I Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerWeill Medical College of Cornell UniversityPhase 1

See all TVB-2640 clinical trials

Clinical Trial Summary for TVB-2640

Top disease conditions for TVB-2640
Top clinical trial sponsors for TVB-2640

See all TVB-2640 clinical trials

US Patents for TVB-2640

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TVB-2640 ⤷  Start Trial Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA) ⤷  Start Trial
TVB-2640 ⤷  Start Trial Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer Sagimet Biosciences Inc ⤷  Start Trial
TVB-2640 ⤷  Start Trial Heterocyclic modulators of lipid synthesis Saginiet Biosciences Inc , Sagimet Biosciences Inc ⤷  Start Trial
TVB-2640 ⤷  Start Trial Pharmaceutical compositions for combination therapy Genfit SA ⤷  Start Trial
TVB-2640 ⤷  Start Trial FXR (NR1H4) modulating compounds Gilead Sciences Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TVB-2640

Drugname Country Document Number Estimated Expiration Related US Patent
TVB-2640 Canada CA2979696 2035-03-19 ⤷  Start Trial
TVB-2640 China CN107428728 2035-03-19 ⤷  Start Trial
TVB-2640 European Patent Office EP3277675 2035-03-19 ⤷  Start Trial
TVB-2640 Spain ES2910049 2035-03-19 ⤷  Start Trial
TVB-2640 Japan JP2018508547 2035-03-19 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

TVB-2640 (Denifanstat) Development Update and Market Projection

Last updated: September 8, 2026

TVB-2640, now known as denifanstat, is an oral fatty acid synthase inhibitor developed by Sagimet Biosciences for metabolic dysfunction-associated steatohepatitis (MASH), formerly nonalcoholic steatohepatitis (NASH). The drug has generated positive Phase 2b biopsy data but remains investigational, with no FDA approval, commercial sales, Orange Book listing, or established exclusivity period as of June 2024.

Sagimet’s lead development strategy is focused on MASH patients with fibrosis, particularly those with stage F2 or F3 disease. If late-stage trials confirm the Phase 2b findings, denifanstat could compete in a market shaped by resmetirom, GLP-1 therapies, incretin combinations, and emerging anti-fibrotic agents.

What is TVB-2640 and how does denifanstat work?

Denifanstat is a selective inhibitor of fatty acid synthase, or FASN. FASN catalyzes de novo lipogenesis, the process by which cells synthesize fatty acids. In MASH, excessive lipid synthesis contributes to hepatic steatosis, inflammation, hepatocyte injury, and fibrosis.

The development rationale includes several potential effects:

  • Reduction of hepatic fat synthesis.
  • Lower liver fat content and inflammation.
  • Improvement in hepatocyte ballooning and lobular inflammation.
  • Potential reduction in fibrotic progression.
  • Activity in extrahepatic tissues associated with metabolic disease.

Denifanstat is an oral, once-daily small molecule. Its mechanism differs from resmetirom, which activates thyroid hormone receptor beta, and from GLP-1 receptor agonists, which primarily affect weight, glucose control, and appetite.

Core development profile

Attribute Denifanstat profile
Development code TVB-2640
International nonproprietary name Denifanstat
Developer Sagimet Biosciences
Mechanism Selective fatty acid synthase inhibitor
Administration Oral
Lead indication MASH with liver fibrosis
Regulatory status Investigational
FDA approval None
Current commercial status Not marketed
Primary development stage Phase 2b completed; Phase 3 planning required
Key trial FASCINATE-2
Main safety issue Acne and related dermatologic adverse events

What were the most important denifanstat clinical trial results?

Sagimet reported positive 52-week biopsy results from the Phase 2b FASCINATE-2 trial in 2024. The study evaluated denifanstat in patients with MASH and stage F2 or F3 fibrosis.

The company reported that denifanstat achieved statistically significant improvement in the key histologic measures used in MASH drug development:

  1. MASH resolution without worsening of fibrosis.
  2. At least one-stage fibrosis improvement without worsening of MASH.
  3. A combined response involving both MASH resolution and fibrosis improvement.

The trial also reported reductions in liver fat and improvements in markers of liver injury. These findings supported continued development, but they do not establish approval-level efficacy. FDA approval requires successful late-stage evidence, an acceptable benefit-risk profile, and agreement on the regulatory endpoint package.

FASCINATE-2 development summary

Parameter Publicly reported information
Trial phase Phase 2b
Population Patients with MASH and F2-F3 fibrosis
Treatment period Approximately 52 weeks
Primary assessment Liver biopsy
Histology endpoints MASH resolution and fibrosis improvement
Reported outcome Statistically significant activity on key histologic measures
Main tolerability signal Acne and dermatologic adverse events
Regulatory consequence Supports Phase 3 planning, but does not constitute approval

The clinical profile is commercially relevant because fibrosis improvement remains one of the most valuable endpoints in MASH. Many competing programs reduce liver fat or improve metabolic parameters without demonstrating clear anti-fibrotic activity.

When could denifanstat reach FDA approval?

Denifanstat is not approved and has no publicly established approval date. The likely regulatory sequence is a Phase 3 program followed by a New Drug Application if the confirmatory trials succeed.

A reasonable development timeline is:

Milestone Potential timing
Phase 2b data reported 2024
Phase 3 design and regulatory alignment 2024-2025
Phase 3 enrollment 2025-2026
First pivotal readout 2027-2028
NDA submission 2028-2029
Potential FDA decision 2029-2030
Potential U.S. launch 2029-2030

This timeline assumes rapid financing, timely trial recruitment, and no requirement for an additional confirmatory study. MASH trials often face lengthy enrollment because patients must undergo liver biopsy, have defined fibrosis stages, and meet multiple metabolic and hepatic eligibility criteria.

What is the FDA regulatory status of TVB-2640?

Denifanstat has no FDA approval, no approved label, and no commercial indication. Public development materials have emphasized the FDA’s MASH guidance and histologic endpoints used in prior regulatory programs.

Resmetirom, marketed as Rezdiffra by Madrigal Pharmaceuticals, became the first FDA-approved treatment for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis, in combination with diet and exercise, in March 2024.[1] That approval establishes a regulatory precedent but also raises the commercial standard for later entrants.

Denifanstat could seek approval through the traditional NDA pathway. Accelerated approval may be possible if the FDA accepts a surrogate endpoint that is reasonably likely to predict clinical benefit, but the regulatory pathway will depend on the strength and durability of the Phase 3 data.

What patents protect denifanstat?

The public record identifies Sagimet as the principal developer of denifanstat and reflects a broader intellectual-property position covering FASN inhibition, chemical compounds, pharmaceutical compositions, and therapeutic uses. The precise patent estate requires claim-by-claim review across U.S., European, and international prosecution records.

The key patent categories are likely to include:

  • Composition-of-matter claims covering denifanstat and related analogues.
  • Salt, polymorph, and crystalline-form claims.
  • Pharmaceutical composition claims.
  • Oral dosing and treatment-method claims.
  • MASH, NASH, fibrosis, and oncology indications.
  • Manufacturing and synthetic-process claims.

No FDA Orange Book listing exists because denifanstat has not been approved. Consequently, there is no current Orange Book patent certification framework or Paragraph IV litigation directed at an approved denifanstat product.

Patent and exclusivity position

Issue Current status
Approved product None
Orange Book listing None
FDA regulatory exclusivity None currently available
Paragraph IV challenges None publicly established against an approved product
Composition-of-matter protection Expected to be central to the estate
Method-of-use protection Relevant for MASH and fibrosis indications
Generic entry Not applicable before approval
Biosimilar entry Not applicable because denifanstat is a small molecule

The commercial value of the patent estate will depend on the earliest enforceable composition-of-matter expiration, patent-term adjustment, possible patent-term extension, and the breadth of surviving claims after prosecution and litigation.

How strong is the denifanstat patent estate?

The estate has strategic value if the core molecule claims extend materially beyond a potential 2029-2030 launch. Composition-of-matter protection would provide the strongest barrier because generic applicants would need to avoid or invalidate the foundational claims. Method-of-use patents would be weaker if alternative FASN inhibitors or label strategies can reach the same patient population.

The main patent risks are:

  • Narrow claim scope after prosecution.
  • Prior-art attacks against the FASN inhibitor chemical series.
  • Patent expiration before full commercial uptake.
  • Generic challenges based on noninfringement or invalidity.
  • Limited protection for a broad MASH indication if claims are restricted to particular fibrosis stages.
  • Dependence on formulation or dosing patents after core molecule expiry.

Unlike biologic therapies, denifanstat would not receive biosimilar exclusivity or biologic patent protections. Generic competition could be rapid after loss of meaningful small-molecule patent protection.

Which companies are challenging or competing with denifanstat?

Denifanstat is entering a competitive MASH market with different therapeutic mechanisms and development stages.

Company Product Mechanism Development or commercial position
Madrigal Pharmaceuticals Resmetirom THR-beta agonist FDA-approved in 2024
Novo Nordisk Semaglutide GLP-1 receptor agonist MASH development
Eli Lilly Tirzepatide GIP/GLP-1 agonist MASH development
89bio Pegozafermin FGF21 analogue Late-stage development
Akero Therapeutics Efruxifermin FGF21 analogue Late-stage development
Viking Therapeutics VK2809 THR-beta agonist Mid- to late-stage development
InventisBio Denifanstat-related competitive programs Various Emerging competition
Sagimet Biosciences Denifanstat FASN inhibitor Phase 2b completed

Resmetirom has the first-mover advantage, but denifanstat could differentiate through its mechanism, oral administration, and possible activity across fibrosis and inflammatory endpoints. Weight loss will also affect prescribing decisions. GLP-1 and incretin therapies may capture patients whose primary treatment objective is obesity or diabetes, while denifanstat could target patients requiring a liver-directed therapy.

What is the market opportunity for denifanstat?

MASH affects a large population, but the near-term treated market will be substantially smaller than total prevalence. Diagnosis, biopsy or noninvasive staging, specialist access, payer restrictions, and competing metabolic therapies will limit initial uptake.

A practical commercial framework is:

Scenario Eligible treated patients by 2035 Annual net price Peak annual sales
Downside 150,000 $15,000 $2.3 billion
Base case 400,000 $20,000 $8.0 billion
Upside 800,000 $25,000 $20.0 billion

These figures are scenario estimates, not company guidance. They assume approval for patients with clinically meaningful fibrosis and pricing below or near specialty hepatology levels established by competing products.

Denifanstat’s commercial upside would increase if it demonstrates:

  • Histologic fibrosis improvement.
  • Benefits in noncirrhotic F2-F3 disease.
  • Compatibility with GLP-1 or incretin therapy.
  • Limited weight gain and acceptable metabolic effects.
  • A clean enough safety profile for chronic use.
  • Noninvasive monitoring that reduces the need for repeat biopsy.

Acne could restrict adherence or physician comfort, especially if the adverse event is dose-related or requires dermatologic management. Chronic MASH treatment requires long-term tolerability because the disease progresses over years.

What generic launch risks exist for denifanstat?

Generic launch risk is low before approval and commercial launch because no generic pathway can be practically pursued against an unapproved reference product. After approval, risk will depend on the remaining patent term.

The highest-risk period would begin when the composition-of-matter patent approaches expiry. Generic applicants could file Abbreviated New Drug Applications with Paragraph IV certifications against listed patents. Litigation would likely focus on:

  • Validity of the core chemical claims.
  • Infringement by generic formulations.
  • Scope of fibrosis and MASH method claims.
  • Written-description and enablement issues.
  • Obviousness based on earlier FASN inhibitor disclosures.

A successful formulation patent could delay entry only if it protects a commercially necessary dosage form. Method-of-use patents may be less effective if generic labels carve out the patented indication.

How does denifanstat compare with resmetirom?

Resmetirom has a major regulatory advantage because it is approved and has established reimbursement pathways. Denifanstat could compete if its fibrosis data are at least comparable and its safety profile is favorable.

Category Denifanstat Resmetirom
Mechanism FASN inhibitor THR-beta agonist
FDA status Investigational Approved
Administration Oral Oral
Target population MASH with fibrosis under development Noncirrhotic MASH with F2-F3 fibrosis
Key differentiation Direct inhibition of fatty-acid synthesis Liver-directed thyroid hormone signaling
Commercial risk Development and safety execution Reimbursement, tolerability, and market expansion
Generic risk No immediate risk before approval Longer-term small-molecule risk

Denifanstat would need to establish either superior efficacy, better tolerability, meaningful combination value, or a lower net price to displace an established resmetirom prescription.

What licensing deals affect TVB-2640?

Denifanstat originated from the 3-V Biosciences research platform and was subsequently advanced by Sagimet Biosciences. Public company materials identify Sagimet as the current developer. The publicly available record does not establish a major late-stage commercialization partnership comparable to a large pharmaceutical co-development agreement.

The absence of a major partner creates both flexibility and financing risk. Sagimet retains strategic control but may need additional capital or a licensing transaction to fund global Phase 3 development and commercialization.

Key Takeaways

  • TVB-2640 is denifanstat, an oral FASN inhibitor developed by Sagimet Biosciences.
  • The drug produced positive Phase 2b biopsy results in patients with MASH and F2-F3 fibrosis.
  • It is not FDA-approved and has no Orange Book listing or current regulatory exclusivity.
  • A Phase 3 program is the critical next development step.
  • A realistic approval and launch window is 2029-2030 if Phase 3 development begins promptly and succeeds.
  • Resmetirom is the principal approved comparator and has a first-mover advantage.
  • Commercial peak sales could range from roughly $2 billion to $20 billion depending on efficacy, safety, pricing, reimbursement, and market penetration.
  • The patent estate’s value depends primarily on the remaining term and enforceability of composition-of-matter claims.
  • Acne and chronic-use tolerability are material commercial risks.
  • Biosimilar competition is irrelevant because denifanstat is a small molecule; generic competition would emerge after small-molecule patent expiry.

FAQs About TVB-2640 and Denifanstat

Is TVB-2640 the same drug as denifanstat?

Yes. TVB-2640 is the development code for denifanstat, Sagimet Biosciences’ oral FASN inhibitor.

Has denifanstat been approved for MASH?

No. Denifanstat remains investigational. Resmetirom is the first FDA-approved therapy for adults with noncirrhotic MASH and moderate-to-advanced fibrosis.

What phase is denifanstat in?

Denifanstat completed a positive Phase 2b program, including the FASCINATE-2 biopsy trial. A successful Phase 3 program is required before potential FDA approval.

Could denifanstat be used with GLP-1 drugs?

Combination use is commercially plausible because FASN inhibition and GLP-1 or incretin therapy act through different mechanisms. A combination strategy would require clinical evidence, safety data, and regulatory support.

What is the biggest risk to denifanstat’s value?

The largest risks are failure to reproduce Phase 2b histology results in Phase 3, chronic dermatologic tolerability issues, competition from approved and late-stage therapies, and insufficient patent life at launch.

References

  1. U.S. Food and Drug Administration. (2024, March 14). FDA approves first treatment for patients with liver scarring due to fatty liver disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

  2. Sagimet Biosciences Inc. (2024). Sagimet announces positive topline results from the Phase 2b FASCINATE-2 trial of denifanstat in MASH. Company press release.

  3. ClinicalTrials.gov. (2024). A study of denifanstat in patients with non-alcoholic steatohepatitis: FASCINATE-2. U.S. National Library of Medicine. https://clinicaltrials.gov/

  4. Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., et al. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835.

  5. Sagimet Biosciences Inc. (2024). Corporate presentations and investor materials. Company investor-relations materials.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.